Acticor Biotech SAS (ALACT.PA)

0.6020 -0.2580 (-30.00%) At close: 05:37PM CEST

Acticor Biotech SAS

Hôpital Bichat
INSERM U1148 46 rue Henri Huchard
Paris 75018
France
33 6 76 23 38 13
https://www.acticor-biotech.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 31

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Gilles Avenard M.D.	Founder, CEO & Director	361.67k	N/A	1951
Ms. Sophie Lebel-Binay Ph.D.	Deputy CEO, Chief Scientific Officer & GM	238.94k	N/A	1968
Dr. Yannick Pletan M.D., M.Sc.	Deputy CEO, GM & Chief Medical Officer	279.91k	N/A	1953
Mr. Philippe Billiald Ph.D., Pharm.D.	Scientific Founder	N/A	N/A	N/A
Ms. Martine Jandrot-Perrus M.D., Ph.D.	Scientific Founder	N/A	N/A	N/A
Mr. Eric Cohen	Chief Financial Officer	N/A	N/A	N/A
Mr. Aymeric Humblot	Head of Finance & Administration	N/A	N/A	N/A
Ms. Laurie Jullien Pharm.D.	Head of Regulatory Affairs	N/A	N/A	N/A
Ms. Kristell Lebozec Ph.D.	Head of Pharmaceutical Development	N/A	N/A	N/A
Ms. Victoria Rutman Pharm.D.	Head of Quality Assurance	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It's product glenzocimab is in Phase 2/3 clinical trial, as well as completed Phase 1b/2a for the treatment of acute ischemic stroke; and Phase 2/3 clinical trial for treatment of cerebrovascular accidents in emergency situations, as well as completed Phase 2 clinical trial for treating acute respiratory distress syndrome (covid-19). The company has collaboration agreement with the University of Birmingham for Phase 2b clinical trials of glenzocimab in treating heart attacks. The company was incorporated in 2013 and is headquartered in Paris, France.

Corporate governance

Acticor Biotech SAS’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.